Research and development with b cells in 2012

0 comments

Posted on 18th March 2017 by Jeff Rogers in Marketing |Technology

With the latest block buster drug to go generic this month the pharmaceutical model for R&D is having to make some major shifts. No longer are big revenues from several products going to help fuel innovation and research, rather bitoech drugs are going to be the next big thing.The more specialized a medicine becomes the more costly it becomes as there are not enough in overall sales to help justify the development. There are multiple ways that companies are studying the impact of b cells and other specific genetic cells to create a more targeted approach. This is why finding ways and solutions to bring therapies to market at a faster pace with lower R&D cost will be more sustainable over the long term.

Research and development with b cells in 2012

0 comments

Posted on 9th March 2017 by Jeff Rogers in Marketing |Technology

With the latest block buster drug to go generic this month the pharmaceutical model for R&D is having to make some major shifts. No longer are big revenues from several products going to help fuel innovation and research, rather bitoech drugs are going to be the next big thing.The more specialized a medicine becomes the more costly it becomes as there are not enough in overall sales to help justify the development. There are multiple ways that companies are studying the impact of b cells and other specific genetic cells to create a more targeted approach. This is why finding ways and solutions to bring therapies to market at a faster pace with lower R&D cost will be more sustainable over the long term.